Arrowhead Pharmaceuticals Inc (ARWR)
Interest coverage
| Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | -184,165 | -172,278 | -140,846 | -93,159 | 61,191 |
| Interest expense | US$ in thousands | 18,326 | 0 | 0 | 9,190,500 | 6,957,770 |
| Interest coverage | -10.05 | — | — | -0.01 | 0.01 |
September 30, 2023 calculation
Interest coverage = EBIT ÷ Interest expense
= $-184,165K ÷ $18,326K
= -10.05
I'm sorry, but the information provided for Arrowhead Pharmaceuticals Inc.'s interest coverage seems to be incorrect or incomplete. The interest coverage ratio is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense. However, the negative value of -67.72 for 2023 indicates that the company's EBIT is insufficient to cover its interest expense. The lack of data for previous years further complicates the analysis. It's important to note that negative interest coverage suggests a potential risk of insolvency and may deter potential lenders and investors. It's advisable to verify the data and gather additional information to assess the company's financial performance accurately.
Peer comparison
Sep 30, 2023